Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Leases (2019 - 2025)

Iovance Biotherapeutics has reported Current Leases over the past 4 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Current Leases at $4.0 million for Q4 2025, down 68.65% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (down 68.65% YoY), and the annual figure for FY2025 was $4.0 million, down 68.65%.
  • Current Leases for Q4 2025 was $4.0 million at Iovance Biotherapeutics, down from $6.3 million in the prior quarter.
  • Over the last five years, Current Leases for IOVA hit a ceiling of $12.9 million in Q4 2024 and a floor of $4.0 million in Q4 2025.
  • Median Current Leases over the past 3 years was $9.5 million (2023), compared with a mean of $9.2 million.
  • Biggest five-year swings in Current Leases: surged 65.82% in 2024 and later plummeted 68.65% in 2025.
  • Iovance Biotherapeutics' Current Leases stood at $7.8 million in 2023, then surged by 65.82% to $12.9 million in 2024, then plummeted by 68.65% to $4.0 million in 2025.
  • The last three reported values for Current Leases were $4.0 million (Q4 2025), $6.3 million (Q3 2025), and $7.1 million (Q2 2025) per Business Quant data.